Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2021 | Comparing therapy benefit from initially HER2 positive or negative metastatic breast cancer patients

Hans-Christian Kolberg • 26 May 2021
ASCO 2021
Breast Cancer

Hans-Christian Kolberg, MD, Marien Hospital Bottrop, Bottrop, Germany, discusses the results of an analysis from the PRAEGNANT prospective breast cancer registry (NCT02338167), comparing progression-free survival (PFS) with standard HER2 targeted therapies between patients with tumors initially HER2-negative and switched to HER2 positive and patients with tumors that were initially HER2 positive adjusted for age and hormone receptor status. In this small cohort, median PFS and 1- and 2-year PFS rates seem to be better in patients HER2 positive at initial diagnosis receiving standard HER2 directed therapies. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.

More from Hans-Christian Kolberg

Management of immune-related AEs during ICI therapy in the clinic
1:36
Management of immune-related AEs during ICI therapy in the clinic
Hans-Christian Kolberg • 12 Dec 2024
Predictive biomarkers for response to checkpoint inhibitors in TNBC
2:00
Predictive biomarkers for response to checkpoint inhibitors in TNBC
Hans-Christian Kolberg • 12 Dec 2024
Subgroup analysis from NeoMono: PD-L1 status and pCR in high-risk eTNBC
3:58
Subgroup analysis from NeoMono: PD-L1 status and pCR in high-risk eTNBC
Hans-Christian Kolberg • 12 Dec 2024
NeoMono: mono atezolizumab window followed by atezolizumab - CTX vs atezolizumab - CTX
3:57
NeoMono: mono atezolizumab window followed by atezolizumab - CTX vs atezolizumab - CTX
Hans-Christian Kolberg • 7 Dec 2022

Related Videos

How will SARMs fit into the current breast cancer treatment paradigm?
1:14
How will SARMs fit into the current breast cancer treatment paradigm?
Rafael Grochot • 2 Jul 2026
Phase I/II trial of vosilasarm and endocrine therapy in AR+/ER+/HER2− breast cancer
1:35
Phase I/II trial of vosilasarm and endocrine therapy in AR+/ER+/HER2− breast cancer
Rafael Grochot • 2 Jul 2026
HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
1:07
HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
Sanjoy Chatterjee • 17 May 2026
Design and aim of the HYPORT study in regional nodal breast cancer
1:23
Design and aim of the HYPORT study in regional nodal breast cancer
Sanjoy Chatterjee • 17 May 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals